GoodRx, a resource for healthcare savings and information, is working with Sanofi, a company that specializes in diabetes care, to offer people living with diabetes access to Lantus (insulin glargine ...

A pharmacist holds a box of the drug Lantus SoloStar, made by Sanofi Pharmaceutical, at a pharmacy in Provo (Reuters) - GoodRx said on Thursday it has collaborated with Sanofi to offer the drugmaker's ...

Sanofi will cut insulin prices by 70% or more and cap out-of-pocket costs at $35 for people with commercial insurance Sanofi follows Eli Lilly and Novo Nordisk in announcing insulin price cuts.

March 16 (Reuters) - Sanofi SA (SASY.PA), opens new tab said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by ...

GoodRx announced Thursday morning that it is working with Sanofi on a program to offer one of its leading insulin products to consumers for $35 per month. By visiting ...

(Reuters) - GoodRx said on Thursday it has collaborated with Sanofi to offer the drugmaker's most-prescribed insulin injection Lantus for only $35 through its digital marketplace in the U.S. All ...

Oct 19 (Reuters) - GoodRx (GDRX.O), opens new tab said on Thursday it has collaborated with Sanofi (SASY.PA), opens new tab to offer the drugmaker's most-prescribed insulin injection Lantus for only ...